Ortin Laboratories Ltd
NSE:ORTINLAB
Relative Value
The Relative Value of one ORTINLAB stock under the Base Case scenario is 2.49 INR. Compared to the current market price of 19.63 INR, Ortin Laboratories Ltd is Overvalued by 87%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ORTINLAB Competitors Multiples
Ortin Laboratories Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
O
|
Ortin Laboratories Ltd
NSE:ORTINLAB
|
159.6m INR | 29.3 | -2.1 | -2.5 | -2.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
948.8B USD | 16 | 51.5 | 34.6 | 37.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563B USD | 6 | 21 | 14.6 | 17.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF | 4.7 | 30.4 | 12.8 | 15 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.6B GBP | 5.1 | 31.5 | 15 | 22 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.1B USD | 4.5 | 15.1 | 10.7 | 12.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
224.1B CHF | 5.1 | 20 | 12.6 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.3 | 13.1 | 9.1 | 10.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD | 2.3 | 14.9 | 7.6 | 10.3 | |
| FR |
|
Sanofi SA
PAR:SAN
|
98.2B EUR | 1.7 | 8.2 | 7.7 | 7.7 |